For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > Investor Relations

Investor Relations

Overview

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Events & Presentations

Upcoming

More events are coming soon.

View All Events

Prior

Monday April 6, 2020 at 8:00 AM EDT
Ruxolitinib Cream: Phase 3 Data in Atopic Dermatitis

View All Events

Press Releases

August 4, 2020

Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs


July 31, 2020

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)


July 23, 2020

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints


View All Releases

Investor Contacts

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Annual Reports

Quarterly Reports

RSS Feeds


All Press Releases

All Events

All SEC Filings